Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2011

01-02-2011 | Editorial

Changes in leadership of breast cancer research and treatment

Author: Marc E. Lippman

Published in: Breast Cancer Research and Treatment | Issue 3/2011

Login to get access

Excerpt

We would like to take this opportunity to thank Professor Daniel Hayes for his wonderful service and leadership as an Associate Editor of Breast Cancer Research and Treatment. Our journal averages around five submissions a day 365 days a year and Dan has ably overseen many of the clinical manuscripts submitted. Not only has he done this with timeliness, sympathy, and wonderful judgment, but in addition has led substantial improvement in policy and guidelines for articles on prognostic variables and other areas. …
Metadata
Title
Changes in leadership of breast cancer research and treatment
Author
Marc E. Lippman
Publication date
01-02-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1350-4

Other articles of this Issue 3/2011

Breast Cancer Research and Treatment 3/2011 Go to the issue

Preclinical Study

COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients

Brief Report

A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance

Clinical trial

Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability

Invited Commentary

Breast cancer prognostic markers in the post-genomic era

Clinical trial

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer

Clinical trial

Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits